Annexon, Inc.
NASDAQ:ANNXBiotechnology
-$0.04 today
- Market cap
- $576.73M
- Beta
- 1.18
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$1.01
Volume 2.98M
Average 2.56M
ANNX Operating Cash Flow
Cash generated by the company's core business operations during the period.
Annexon, Inc.NASDAQ: ANNX
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow dips below year-ago levels
Q1 FY2026 operating cash flow of $46.8M (cash outflow) fell 6.5% year over year, behind the +31.0% change in trailing-twelve-month operating cash flow. Sequentially, it rose 1.9% from the prior quarter. Over 3 fiscal years it compounded at +17.0% a year.
Context
- Operating cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -6.5% toward the trailing-twelve-month pace of +31.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (186.36M) USD
- Year-over-year change
- -57.9%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (186.36M) | -57.9% |
| FY2024 | 2024-12-31 | (118.01M) | +2.6% |
| FY2023 | 2023-12-31 | (121.14M) | -4.2% |
| FY2022 | 2022-12-31 | (116.31M) | -9.6% |
| FY2021 | 2021-12-31 | (106.11M) | — |
Operating Cash Flow vs competitors
How ANNX compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +31.0% is the 4th highest of 11, against a peer median of -3.6%.
- Over three fiscal years its annual growth of +17.0% compares with a peer median of +22.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $395M USD | -8.3% | +29.4% | 5567.4% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $351.4M USD | +1.8% | +50.8% | 4749.9% |
| LTM Jun 2026 | $205.81M USD | +53.4% | — | 196.1% | |
| LTM Mar 2026 | $183.1M USD | +31.0% | +17.0% | — | |
| FY2025 | €155.69M EUR | +1.1% | +42.4% | — | |
| LTM Mar 2026 | $81.34M USD | -37.6% | +14.6% | 140.4% | |
| LTM Dec 2025 | CHF 69.2M CHF | -205.1% | -3.5% | 1936.8% | |
| LTM Mar 2026 | $52.21M USD | +323.8% | -11.3% | 623.9% | |
| LTM Mar 2026 | €28.81M EUR | -39.6% | +0.2% | 98232.5% | |
| LTM Mar 2026 | $27.4M USD | -58.3% | +45.2% | 51.0% | |
| LTM Mar 2026 | $4.48M USD | +104.1% | — | 1.9% | |
| Peer median (excluding ANNX) | — | -3.6% | +22.0% | 623.9% | |
Competitors are the stored peer set for ANNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (130.32M) | (141.95M) | (134.24M) | (138.2M) | (206.69M) |
| Depreciation & Amortization | 3.41M | 2.11M | 2.15M | 2.15M | 2.17M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 18.52M | 18.18M | 19.43M | 16.42M |
| Change in Working Capital | 3.28M | 3.74M | (5.81M) | 6.36M | 4.23M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.86M | (287K) | (2.08M) | 4.94M | 4.49M |
| Other Working Capital | (575K) | 4.03M | (3.73M) | 1.43M | (261K) |
| Other Non-Cash Items | 17.52M | 1.28M | (1.43M) | (7.75M) | (2.49M) |
| Operating Cash Flow | (106.11M) | (116.31M) | (121.14M) | (118.01M) | (186.36M) |
| Capital Expenditures | (1.65M) | (6.53M) | (193K) | (15K) | (137K) |
| Acquisitions (Net) | 0 | (64.97K) | 0 | 0 | 0 |
| Purchases of Investments | (225.6M) | (113.2M) | (108.09M) | (583.93M) | (212.21M) |
| Sales of Investments | 139.02M | 178.17M | 178.98M | 365.15M | 402.4M |
| Other Investing Activities | 0 | 64.97K | 0 | 0 | 0 |
| Investing Cash Flow | (88.24M) | 58.44M | 70.7M | (218.8M) | 190.05M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.8M | 130.48M | 135.51M | 161.87M | 110.47M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | (1.86M) |
| Other Financing Activities | 0 | (7.57M) | 14K | (665K) | 238K |
| Financing Cash Flow | 1.8M | 122.91M | 135.52M | 161.21M | 108.86M |
| Effect of Forex Changes | (1.17M) | 1K | 5K | (15K) | 2K |
| Net Change in Cash | (193.72M) | 65.04M | 85.09M | (175.61M) | 112.55M |
| Free Cash Flow | (107.76M) | (122.84M) | (121.34M) | (118.02M) | (186.49M) |
Annexon, Inc.
NASDAQ:ANNX
Intrinsic Alpha fair value
Locked
Current Price
$3.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.